“Cost-effectiveness analysis of paclitaxel + carboplatin vs. alternative combinations in the treatment of non-small cell lung cancer” (2006) Farmeconomia. Health economics and therapeutic pathways, 7(2), pp. 97–117. doi:10.7175/fe.v7i2.680.